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DCs redirect T cell trafﬁc
 
Dendritic cells (DCs) are the master regulators of T cell 
recirculation, according to a study by Mora et al. on 
page 303. Memory T cells—thought to be programmed 
to return to the location in which they first 
encountered antigen—can be rerouted by an encounter 
with a DC from another location.
Previous studies have shown that memory T cells 
express a characteristic array of adhesion molecules 
and chemokine receptors on their surface that reflect 
the location of activation and direct their trafficking 
back to that site. Recently, this group showed that gut 
DCs, but not spleen or peripheral lymph node DCs, 
induced the up-regulation of the gut-homing integrin 
 
 
 
4
 
 
 
7 on T cells.
Mora et al. now show that these “committed” T 
cells are not set in their ways. In vitro, T cells 
stimulated with skin-derived DCs and later restimulated with gut-derived DCs 
quickly replaced their skin-homing molecules with the gut-homing variety 
(and vice versa), demonstrating that recirculating T cells simply obey the 
signals provided by the most recently encountered DC. In vivo, tissue-specific 
effector–memory T cells can revert to central–memory status, thus acquiring 
the capacity to home to a variety of second lymphoid tissue where they can 
encounter new instructions from resident DCs.
This plasticity may be important, points out senior author Ulrich von 
Andrian, as it would allow the immune system to fight off pathogens that can 
colonize more than one site. It might also provide a new approach to treating T 
cell–mediated inflammatory diseases, if harmful T cells can be diverted to an 
innocuous site.
T cell trafficking 
patterns can be changed 
after encounter with a 
dendritic cell from a 
new location.
 
Surviving rapamycin
 
T cell survival in the face of the immuno-
suppressive drug rapamycin depends on
the expression of prosurvival proteins
Pim-1 and Pim-2, according to a report
by Fox et al. on page 259. Pim-1 and
Pim-2 transmit signals that compensate
for those that are wiped out by rapamycin;
without the Pim proteins, rapamycin
is deadly.
Rapamycin, a drug used to pre-
vent rejection of transplants in humans,
blocks the activation of a protein kinase
called TOR (target of rapamycin), a
component of a T cell signaling pathway
that is important for cell survival and
activation. Rapamycin works in trans-
plant patients, but treatment of T cells
with this drug in vitro or elimination of
a signaling protein upstream of TOR in
mice has little effect on T cell activation
or survival. This paradox, says senior
author Craig Thompson, is “rapamycin’s
failed in two respects: they did not turn
on activation signals in response to
TCR ligation and they were unable
to respond to cytokine-driven survival
signals. Wild-type cells, however, acti-
vated the TCR pathway and survived
as well as untreated cells. Thus, the Pim
proteins provide the only alternative
signaling pathway that can bypass the
defect inflicted by rapamycin.
The debilitating consequences of
lacking Pim-1 and Pim-2 are in part due
to an inability to phosphorylate and thus
inactivate the proapoptotic protein Bad.
Without the Pim proteins, Bad runs
rampant. Whether activated Bad is the
sole cause of the effects seen in the absence
of Pim-1 and Pim-2 is not yet known,
but future studies using Bad-deficient
mice will reveal if other mechanisms
are also at play. Why rapamycin works
in patients who have no known de-
fects in the Pim proteins remains a
mystery.
 
dirty little secret.” The new work es-
tablishes the mechanism behind half of
this secret.
Thompson’s group now shows that
rapamycin’s lack of effect in vitro and in
mice is due to the expression of protein
kinases Pim-1 and Pim-2, which are
activated by growth-promoting cytokines
and TCR ligation. T cells lacking both
Pim proteins and treated with rapamycin
Pim-1 and Pim-2 are essential for T cell 
growth and survival in the presence of 
rapamycin.
 
UV-induced T
 
reg
 
 cells
 
A new study explains how UV ex-
posure induces immunosuppres-
sion. Previous studies showed that
UV-induced immunosuppression is
caused by regulatory T cells (T
 
reg
 
cells). On page 173, Schwarz et al.
now show that the development of
T
 
reg
 
 cells requires DNA damage to
DCs called Langerhans cells (LCs).
Mice exposed to UV light are
rendered unresponsive to antigens
applied to skin because of the in-
duction of T
 
reg
 
 cells, which interfere
with activation of effector T cells in
response to antigen. IL-12, a cytokine
produced by LCs, can both prevent
the establishment of the unresponsive
state and can also reverse established
tolerance  when provided in com-
bination  with  antigen stimulation.
Schwarz et al. showed in a previous
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Jump-starting tumor-speciﬁc T cells
 
Vaccination with tumor antigens causes tumor regression in 
some melanoma patients despite negligible expansion of 
vaccine-specific T cells. Vaccination may instead result in the 
expansion of T cells specific for tumor antigens not contained 
in the vaccine, thus facilitating tumor regression, according to 
two articles from Pierre Coulie and colleagues on pages 241 
and 249.
Tumor-specific T cells can be detected in the blood and the 
tumors of many melanoma patients, and yet these cells are 
unable to kill the tumor. What causes the impotence of these T 
cells is a mystery. Equally mysterious is why vaccination against 
tumor-specific antigens sometimes causes regression without 
expanding large numbers of vaccine-specific killer T cells.
Pierre Coulie’s group studied the specificity of antitumor T cell 
responses in patients vaccinated with a tumor antigen called 
MAGE-3. In one patient whose tumors regressed after vaccination, 
the authors found that T cells specific for nonvaccine tumor 
antigens became detectable or expanded from their prevaccine 
frequencies. Vaccine-specific T cells became detectable but 
remained at low frequency. Thus, reinvigoration of existing tumor-
specific T cells and activation of new T cells after vaccination does 
not require large numbers of vaccine-specific T cells.
Although the mechanism underlying this phenomenon 
Tumor-specific T cells (red) infiltrate a tumor after vaccination.
 
 
 
Rethinking EAE pathogenesis
 
Th1 cells have long been thought to mediate 
the pathogenesis of experimental 
autoimmune encephalitis (EAE), a mouse 
model for multiple sclerosis. But Langrish et 
al. now identify a new subset of T cells as the 
driving force behind brain inflammation in 
EAE (page 233).
Previous thinking on EAE culprits has 
focused on Th1 CD4
 
 
 
 T cells and their 
distinctive product IFN-
 
 
 
, both of which are 
found at EAE inflammation sites. But the 
details were confused by the biology of p40—a subunit shared by both IL-12 
(an inducer of Th1 cells) and IL-23. This group showed recently that EAE is 
suppressed after p40 inactivation because of the loss of IL-23 not IL-12.
The authors now explain the pathogenic effect of IL-23 by showing that this 
cytokine induces a newly recognized subset of CD4
 
 
 
 T cells, which produces large 
amounts of IL-17 and IL-6 but very little IFN-
 
 
 
. These T cells and IFN-
 
 
 
–producing 
Th1 cells both invaded the CNS during EAE in wild-type mice, but only IFN-
 
 
 
–
producing Th1 cells were found in the CNS in mice lacking IL-23. Furthermore, 
T cells cultured in vitro with IL-23, but not those cultured with IL-12, could 
transfer the disease to naive mice.
How these cells induce disease is not completely understood. IL-17 appears 
to be a key player, as blocking IL-17 in wild-type mice partially reversed disease. 
IL-17 is known to drive the production of inflammatory cytokines from memory 
T cells, and IL-23 induces proliferation of these cells—both of which may amplify 
inflammation. Whatever the mechanism, this study appears to exonerate 
traditional Th1 cells as the main players in the pathogenesis of EAE.
CD4+ T cells cultured in vitro 
with IL-23 ( ), but not IL-12 
( ) induce EAE pathogenesis.
 
remains unknown, Coulie thinks that the few T cells 
stimulated by the vaccine may change the local environment 
of the tumor such that existing T cells can be reactivated and 
new T cells can be recruited.
 
study that IL-12 also promotes DNA
repair, but it was unclear how (or if)
these functions of IL-12 related to one
another.
The group now shows that the
prevention of UV-induced immuno-
suppression relies on DNA repair. Mice
that lacked the DNA repair machinery
became immunocompromised after UV
exposure even after they were given
IL-12. In wild-type mice, IL-12 pro-
tected against immunosuppression.
Thus, IL-12 interference with im-
munosuppression appears to be de-
pendent on its induction of DNA
repair. The authors suggest that DNA
damage may change the costimula-
tory molecules expressed on LCs,
thus altering their stimulatory pro-
file away from effector T cells and
toward T
 
reg
 
 cells.
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